A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma

Part of paid clinical trials in Los Angeles, California.

Sponsor
Janssen Research & Development, LLC
Study ID
NCT01779791
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • PCI-32765 (Ibrutinib) — DRUG
    560 mg capsules administered orally once daily, continuously on a 21-day cycle until progressive disease.

Study Details

The purpose of this study is to evaluate the efficacy and safety of PCI-32765 (ibrutinib) administered to patients with chemoimmunotherapy-resistant follicular lymphoma (FL).

Key Dates

Start date
Apr 17, 2013
Status verified
Jul 2017
Primary completion
May 18, 2016
Completion
May 18, 2016

Study Design

Enrollment
110 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: PCI-32765 (Ibrutinib)

Primary Outcome Measure

Overall response rate [ Time Frame: Up to 2 years after the last patient is enrolled ]

Locations (20)

FacilityCityStateZIPSite coordinators
-Los AngelesCalifornia--
-StanfordCalifornia--
-Washington D.C.District of Columbia--
-AtlantaGeorgia--
-ChicagoIllinois--
-WestwoodKansas--
-LexingtonKentucky--
-LouisvilleKentucky--
-BaltimoreMaryland--
-DetroitMichigan--
-HackensackNew Jersey--
-New BrunswickNew Jersey--
-New YorkNew York--
-GreenvilleNorth Carolina--
-PortlandOregon--
-PhiladelphiaPennsylvania--
-PittsburghPennsylvania--
-HoustonTexas--
-BurlingtonVermont--
-SeattleWashington--

Related Studies